Adverse events with concomitant amiodarone and statin therapy - Alsheikh-Ali, A. A.; Karas, R. H. (Prev Cardiol, 2005)

A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on CYP3A4 - Andreasen, A. H.; Brøsen, K.; Damkier, P. (Epilepsia, 2007)

Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature - Andrus, M. R. (Pharmacotherapy, 2004)

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) - Ansell, J.; Hirsh, J.; Hylek, E.; Jacobson, A.; Crowther, M.; Palareti, G. (Chest, 2008)

Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population - Bakhai, A.; Rigney, U.; Hollis, S.; Emmas, C. (Pharmacoepidemiol Drug Saf, 2012)

Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics - Becquemont, L.; Neuvonen, M.; Verstuyft, C.; Jaillon, P.; Letierce, A.; Neuvonen, P. J.; Funck-Brentano, C. (Clin Pharmacol Ther, 2007)

Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon - Beinema, M.; Brouwers, J. R. B. J.; Schalekamp, T.; Wilffert, B. (Thromb Haemost, 2008)

Statin drug interactions and related adverse reactions - Bellosta, S.; Corsini, A. (Expert Opin Drug Saf, 2012)

Statin safety and drug interactions: clinical implications - Bottorff, M. B. (Am J Cardiol, 2006)

Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes - Cohen, L. H.; van Leeuwen, R. E.; van Thiel, G. C.; van Pelt, J. F.; Yap, S. H. (Biopharm Drug Dispos, 2000)

Investigation of PK-PD drug-drug interaction between acenocoumarol and amoxicillin plus clavulanic acid - Delavenne, X.; Laporte, S.; Demasles, S.; Mallouk, N.; Basset, T.; Tod, M.; Girard, P.; Mismetti, P. (Fundam Clin Pharmacol, 2009)

Drugs.com. Drug Interactions Checker http://www.drugs.com/drug_interactions.html

Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins - Egger, S. S.; Rätz Bravo, A. E.; Hess, L.; Schlienger, R. G.; Krähenbühl, S. (Drugs Aging, 2007)

An examination of the effect of Cytochrome P450 drug interactions of Hydroxymethylglutaryl-Coenzyme a reductase inhibitors on health care utilization: a Canadian population-based study - Einarson, T. R.; Metge, C. J.; Iskedjian, M.; Mukherjee, J. (Clinical Therapeutics, 2002)

New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury (U.S. Food and Drug Administration 10903, 2011)

Potentially fatal interaction between diltiazem and statins - Gladding, P.; Pilmore, H. (Ann Int Med, 2004)

Simvastatin-oral anticoagulant interaction - Grau, E.; Perella, M.; Pastor, E. (Lancet, 1996)

The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose - Herman, D.; Locatelli, I.; Grabnar, I.; Peternel, P.; Stegnar, M.; Lainscak, M.; Mrhar, A.; Breskvar, K.; Dolzan, V. (Eur J Clin Pharmacol, 2006)

Drug interactions with simvastatin: the risk continues - Horn, J. R.; Hansten, P. D. (Pharmacy Times, 2011)

Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition - Hu, M.; Mak, V. W.; Tomlinson, B. (J Clin Pharm Ther, 2011)

Epidemiology of drug-drug interactions as a cause of hospital admissions - Jankel, C. A.; Fitterman, L. K. (Drug Saf, 1993)

Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis - Kanathur, N.; Mathai, M. G.; Byrd, R. P.; Fields, C. L.; Roy, T. M. (Tenn Med, 2001)

Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations - Kantola, T.; Kivistö, K. T.; Neuvonen, P. J. (Clin Pharmacol Ther, 1998)

Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin - Lee, A. J.; Maddix, D. S. (Ann Pharmacother, 2001)

Rhabdomyolysis with concurrent atorvastatin and diltiazem - Lewin, J. J.; Nappi, J. M.; Taylor, M. H. (Ann Pharmacother, 2002)

Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature - Marot, A.; Morelle, J.; Chouinard, V. A.; Jadoul, M.; Lambert, M.; Demoulin, N. (Acta Clin Belg, 2011)

Efficacy and safety of rosuvastatin in treatment of dyslipidemia - McKenney, J. M. (Am J Health Syst Pharm, 2005)

Medscape. Drug Interaction Checker http://www.medscape.com/druginfo/druginterchecker

Highlights of prescribing information for ZOCOR (simvastatin) (Cramlington, 2008)

Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients - Molden, E.; Andersson, K. S. (Pharmacotherapy, 2007)

Rosuvastatin-Acenocoumarol Interaction - Mondillo, S.; Ballo, P.; Galderisi, M. (Clin Ther, 2005)

Rhabdomyolysis and HMG-CoA reductase inhibitors - Omar, M. A.; Wilson, J. P.; Cox, T. S. (Ann Pharmacother, 2001)

Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy - Rätz Bravo, A. E.; Tchambaz, L.; Krähenbühl-Melcher, A.; Hess, L.; Schlienger, R. G.; Krähenbühl, S. (Drug Saf, 2005)

Rhabdomyolysis in association with simvastatin and amiodarone - Roten, L.; Schoenenberger, R. A.; Krähenbühl, S.; Schlienger, R. G. (Ann Pharmacother, 2004)

Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport - Sakaeda, T.; Fujino, H.; Komoto, C.; Kakumoto, M.; Jin, J. S.; Iwaki, K.; Nishiguchi, K.; Nakamura, T.; Okamura, N.; Okumura, K. (Pharm Res, 2006)

Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction - Schalekamp, T.; van Geest-Daalderop, J. H.; Kramer, M. H.; van Holten-Verzantvoort, A. T.; de Boer, A. (Eur J Clin Pharmacol, 2007)

Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk - Schelleman, H.; Bilker, W. B.; Brensinger, C. M.; Wan, F.; Yang, Y. X.; Hennessy, S. (Am J Med, 2010)

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions - Shitara, Y.; Sugiyama, Y. (Pharmacol Ther, 2006)

Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics - Simonson, S. G.; Martin, P. D.; Mitchell, P. D.; Lasseter, K.; Gibson, G.; Schneck, D. W. (J Clin Pharmacol, 2005)

The coprescription of contraindicated drugs with statins: continuing potential for increased risk of adverse events - Stang, P.; Morris, L.; Kempf, J.; Henderson, S.; Yood, M. U.; Oliveria, S. (Am J Ther, 2007)

Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study - Tirkkonen, T.; Ryynänen, A.; Vahlberg, T.; Irjala, K.; Klaukka, T.; Huupponen, R.; Laine, K. (Drug Saf, 2008)

Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid - Ucar, M.; Neuvonen, M.; Luurila, H.; Dahlqvist, R.; Neuvonen, P. J.; Mjörndal, T. (Eur J Clin Pharmacol, 2004)

Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose - van Schie, R. M.; Verhoef, T. I.; Boejharat, S. B.; Schalekamp, T.; Wessels, J. A.; le Cessie, S.; Rosendaal, F. R.; van der Meer, F. J.; de Boer, A.; der Zee AH, M. -. v. (Drug Metabol Drug Interact, 2012)

Probable warfarin-simvastatin interaction - Westergren, T.; Johansson, P.; Molden, E. (Ann Pharmacother, 2007)

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors - Williams, D.; Feely, J. (Clin Pharmacokinet, 2002)

Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin - Yu, C. Y.; Campbell, S. E.; Zhu, B.; Knadler, M. P.; Small, D. S.; Sponseller, C. A.; Hunt, T. L.; Morgan, R. E. (Curr Med Res Opin, 2012)